CARISMA Therapeutics (CARISMA Therapeutics) FCF Margin % : -660.64% (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is CARISMA Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. CARISMA Therapeutics's Free Cash Flow for the three months ended in Mar. 2024 was $-22.44 Mil. CARISMA Therapeutics's Revenue for the three months ended in Mar. 2024 was $3.40 Mil. Therefore, CARISMA Therapeutics's FCF Margin % for the quarter that ended in Mar. 2024 was -660.64%.

As of today, CARISMA Therapeutics's current FCF Yield % is -130.39%.

The historical rank and industry rank for CARISMA Therapeutics's FCF Margin % or its related term are showing as below:

CARM' s FCF Margin % Range Over the Past 10 Years
Min: -551.71 Med: -325.56 Max: -99.41
Current: -524.66

During the past 4 years, the highest FCF Margin % of CARISMA Therapeutics was -99.41%. The lowest was -551.71%. And the median was -325.56%.

CARM's FCF Margin % is ranked worse than
67.69% of 1046 companies
in the Biotechnology industry
Industry Median: -145.305 vs CARM: -524.66

CARISMA Therapeutics FCF Margin % Historical Data

The historical data trend for CARISMA Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CARISMA Therapeutics FCF Margin % Chart

CARISMA Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

FCF Margin %

-99.41

-551.71

CARISMA Therapeutics Quarterly Data
	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial							-791.52	-527.92	-553.65	-388.39	-660.64

Competitive Comparison of CARISMA Therapeutics's FCF Margin %

For the Biotechnology subindustry, CARISMA Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CARISMA Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CARISMA Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where CARISMA Therapeutics's FCF Margin % falls into.

CARISMA Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

CARISMA Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-82.309	/	14.919
	=	-551.71 %

CARISMA Therapeutics's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-22.442	/	3.397
	=	-660.64 %

CARISMA Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of CARISMA Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

CARISMA Therapeutics (CARISMA Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CARISMA Therapeutics Inc (NAS:CARM) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

W2J:Germany

Address

245 First Street, Suite 1800, Cambridge, MA, USA, 02142

Website

https://www.carismatx.com

CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.

Executives

Modernatx, Inc.	10 percent owner	200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Sanford S Zweifach	director	21720 23RD DRIVE SE, SUITE 150, BOTHELL WA 98021
Steven Kelly	director, officer: President and CEO	C/O INNOVIVE PHARMACEUTICALS, INC., 555 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022
Briggs Morrison	director	C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451
Richard Steven Morris	officer: Chief Financial Officer	397 EAGLEVIEW BOULEVARD, EXTON PA 19341
Chidozie Ugwumba	director	158 FILMORE STREET, DENVER CO 80206
Michael Klichinsky	officer: Chief Scientific Officer	C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Michael Torok	director	C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Regina Hodits	director	C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Bjorn Odlander	director	C/O ODLANDER, FREDRIKSON & CO. AB, STRANDVAGEN 5B, STOCKHOLM V7 SE-114 51
Minori Rosales	officer: Chief Development Officer	245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142
Jewett Michael A. S.	director	C/O SESEN BIO, INC., 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142
Peter Honig	director	3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Patricia M. Drake	officer: Chief Commercial Officer	245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142
Elly Ryu	officer: Principal Accounting Officer	245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142